Work at Shanghai Jeyou Pharmaceutical Co. Ltd. has led to the identification of new thioether-substituted galactopyranoside derivatives acting as galectin-3 (LGALS3) inhibitors.
Shanghai Ailux Biotechnology Co. Ltd. has patented new antibody-drug conjugates consisting of an antibody targeting fibroblast growth factor receptor 2 isoform 2 (FGFR2; FGFR2b) covalently linked to a cytotoxic drug intended for use in the treatment of cancer.
Hangzhou Bio Sincerity Pharma-Tech Co. Ltd. has reported crylamide compounds acting as exportin-1 (CRM1; XPO1) receptor antagonists found to be useful for the treatment of cancer.
The University of California has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase Von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety coupled to cAMP-dependent protein kinase catalytic subunit α (PRKACA) targeting moiety through a linker.
Treeline Biosciences Inc. has disclosed macrocyclic compounds acting as RAS inhibitors that are potentially useful for the treatment of pancreatic cancer (ductal adenocarcinoma) and melanoma.
Impact Therapeutics (Shanghai) Inc. has prepared and tested Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.
Sunrise Oncology (Hong Kong) Ltd. has synthesized new condensed macrocyclic compounds acting as GTPase KRAS inhibitors potentially useful for the treatment of cancer.
RSS